Unraveling the Link Between SGLT2 Inhibition, Circulating Metabolites, and Alzheimer’s Dementia: A Mendelian Randomization Study
Hao Yang, Yuye Ning, Meilin Chen, Jianping Jia · 2025
Read Unraveling the Link Between SGLT2 Inhibition, Circulating Metabolites, and Alzheimer’s Dementia: A Mendelian Randomization Study by Hao Yang, Yuye Ning, Meilin Chen, Jianping Jia (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11712402.txt.
Description
Hao Yang, Jianping Jia and their co-authors use Mendelian randomization to test if diabetes drugs that block SGLT2 lower Alzheimer risk in 2025. People with type two diabetes face higher dementia risk, and these drugs show benefits beyond blood sugar control.
Gene-based proxies for drug action linked to lower risk of both diabetes and Alzheimer disease, for early and late onset forms alike. Among more than one hundred blood metabolites tested, citrate stood out as a possible middleman in the link. The authors say the gene evidence is strong but call for randomized trials to confirm the effect in patients.
Catalog record
| CREATOR | Hao Yang, Yuye Ning, Meilin Chen, Jianping Jia |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |